047 Rare late onset neutropenia in a patient with multiple sclerosis treated with ocrelizumab and review of literature

047 Rare late onset neutropenia in a patient with multiple sclerosis treated with ocrelizumab and review of literature

Bibliographic Details
Main Authors:	Robert McGrath, Shoaib Dal, Babar Malik
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-08-01
Series:	BMJ Neurology Open

Similar Items

Ocrelizumab associated late-onset neutropenia in the patient with multiple sclerosis: Case report and literature review
by: Jovićević Vanja, et al.
Published: (2022-01-01)

The Effect of Ocrelizumab in the Treatment of Multipl Sclerosis
by: Şenay Yıldız Çelik
Published: (2017-09-01)

OCRELIZUMAB IN THE TREATMENT OF PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS
by: E. V. Popova
Published: (2018-02-01)

Ocrelizumab as a breakthrogh in multiple sclerosis treatment
by: Marcin Zaniuk, et al.
Published: (2021-05-01)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
by: Katja Akgün, et al.
Published: (2022-11-01)

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
by: A. N. Boyko, et al.
Published: (2019-11-01)

Ocrelizumab: a new milestone in multiple sclerosis therapy
by: Patricia Mulero, et al.
Published: (2018-05-01)

Neutropenia tóxica tras ocrelizumab sin recurrencias posteriores tras continuar el tratamiento
by: F. Gascon-Gimenez, et al.
Published: (2021-04-01)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
by: Shannon Kolind, et al.
Published: (2022-01-01)

Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series
by: Stefania F. De Mercanti, et al.
Published: (2021-10-01)

Ocrelizumab in treatment of primary-progressive multiple sclerosis: systematic review
by: D. L. Klabukova, et al.
Published: (2018-07-01)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
by: Britney Barrera, et al.
Published: (2023-04-01)

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
by: Stefan Gingele, et al.
Published: (2018-12-01)

Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis
by: Tereza Gabelić, et al.
Published: (2021-11-01)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
by: Frau J, et al.
Published: (2018-04-01)

009 Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study
by: Katherine A Buzzard, et al.
Published: (2021-08-01)

Multiple Sclerosis anti-CD20 (Ocrelizumab) therapy inducing hypogammaglobulinemia
by: Nora Abdul-Aziz, et al.
Published: (2023-12-01)

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
by: Sridhar Chilimuri, et al.
Published: (2021-03-01)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
by: Despoina Florou, et al.
Published: (2020-10-01)

Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
by: Xavier Montalban, et al.
Published: (2023-03-01)

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
by: Juan Ignacio ROJAS, et al.
Published: (2021-06-01)

Role of CD20+ T cells in multiple sclerosis: implications for treatment with ocrelizumab
by: Stefan Gingele, et al.
Published: (2020-01-01)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
by: Angel P. Sempere, et al.
Published: (2021-01-01)

Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe
by: Marcelo Vivolo Aun, et al.
Published: (2022-02-01)

NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy
by: Simone Dal Bello, et al.
Published: (2024-01-01)

An Unexpected Post-ocrelizumab Improvement in Glycaemic Control in a Patient with Multiple Sclerosis
by: Ozge Arici Duz, et al.
Published: (2022-10-01)

Successful rapid desensitization of a pediatric multiple sclerosis patient with anaphylaxis to ocrelizumab
by: Hatice B G. Karaaslan, et al.
Published: (2022-01-01)

097 Case Report: A role for Ocrelizumab for Multiple Sclerosis with Ocular Sarcoidosis?
by: Glenn Reeves, et al.
Published: (2021-08-01)

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
by: Per Soelberg Sorensen, et al.
Published: (2016-01-01)

Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
by: Duarte Diana Borges, et al.
Published: (2021-07-01)

Late onset multiple sclerosis
by: M. Arias, et al.
Published: (2011-01-01)

Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis
by: Annika Klumpp, MD, et al.
Published: (2022-10-01)

Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab
by: Elina Groß-Albenhausen, et al.
Published: (2023-09-01)

Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.
by: Paul Emery, et al.
Published: (2014-01-01)

Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
by: Gabrielle Benesh, BS, et al.
Published: (2021-10-01)

Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
by: Roberta Lanzillo, et al.
Published: (2022-04-01)

Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile
by: D. L. Klabukova, et al.
Published: (2019-06-01)

Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review
by: D. L. Klabukova, et al.
Published: (2018-11-01)

Ocrelizumab‐induced psoriasiform dermatitis: Case reports and review of the literature
by: Natalia Naranjo Guerrero, et al.
Published: (2023-12-01)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
by: Aliya Jaber, et al.
Published: (2023-02-01)